Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Ocugen, Inc. Common Stock (OCGN)

Biological Products, (no Disgnostic Substances)

https://www.ocugen.com

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

11 GREAT VALLEY PARKWAY
MALVERN, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/03/2014

Market Cap

369,897,530

Shares Outstanding

256,500,000

Weighted SO

256,502,434

Total Employees

N/A

Upcoming Earnings

08/19/2024

Similar Tickers

VXRT --.--%

NVAX --.--%

CWBR --.--%

RAIN --.--%

OCEA --.--%

ELEV --.--%

AVRO --.--%

ZURA --.--%

Beta

3.7500

Last Div

0.0000

Range

0.345-2.105

Chg

-0.0250

Avg Vol

5779587

Mkt Cap

369897530

Exch

NASDAQ

Country

US

Phone

484 328 4701

DCF Diff

1.2501

DCF

0.0349

Div Yield

0.0000

P/S

45.1590

EV Multiple

-7.1109

P/FV

19.5368

Div Yield %

0.0000

P/E

-6.5023

PEG

-0.2341

Payout

0.0000

Current Ratio

1.0359

Quick Ratio

1.0359

Cash Ratio

0.8734

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1112.0530

CCC

-1112.0530

Gross Margin

0.8641

Op Margin

-6.3133

Pretax Margin

-6.2091

Net Margin

-6.2091

Eff Tax Rate

0.0008

ROA

-1.2545

ROE

-1.3920

ROCE

-2.2912

NI/EBT

1.0000

EBT/EBIT

0.9835

EBIT/Rev

-6.3133

Debt Ratio

0.0819

D/E

0.1961

LT Debt/Cap

0.0840

Total Debt/Cap

0.1639

Int Coverage

0.0000

CF/Debt

-13.7132

Equity Multi

2.3951

Rec Turnover

0.0000

Pay Turnover

0.3282

Inv Turnover

0.0000

FA Turnover

0.4688

Asset Turnover

0.2020

OCF/Share

-0.1769

FCF/Share

-0.2116

Cash/Share

0.0610

OCF/Sales

-5.5566

FCF/OCF

1.1967

CF Coverage

-13.7132

ST Coverage

-25.7578

CapEx Coverage

-5.0842

Div&CapEx Cov

-5.0842

P/BV

19.5368

P/B

19.5368

P/S

45.1590

P/E

-6.5023

P/FCF

-6.7913

P/OCF

-7.2659

P/CF

-7.2659

PEG

-0.2341

P/S

45.1590

EV Multiple

-7.1109

P/FV

19.5368

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 16, 07:30 Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board MarketWatch Jan 03, 10:10 Nvidia and other stocks "approaching the trough of disillusionment" over GenAI MarketWatch Jan 03, 08:55 Nvidia and other stocks "approaching the trough of disillusionment" over GenAI MarketWatch Jan 03, 06:51 Nvidia and other stocks "approaching the trough of disillusionment" over GenAI GlobeNewswire Inc. Dec 21, 06:30 Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design GlobeNewswire Inc. Dec 19, 07:30 Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations GlobeNewswire Inc. Dec 13, 07:30 Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration GlobeNewswire Inc. Nov 29, 07:30 Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference GlobeNewswire Inc. Nov 10, 07:30 Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease The Motley Fool Nov 09, 11:45 Ocugen (OCGN) Q3 2023 Earnings Call Transcript GlobeNewswire Inc. Nov 07, 07:45 Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit GlobeNewswire Inc. Nov 02, 07:30 Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results

Revenue Product Segmentation